LILRA2產(chǎn)品信息

別稱(chēng)：LILRA2,CD85h,ILT1

物種：Human

屬性：Protein

標(biāo)記：Biotin-labeled/Unconjugated

內(nèi)毒素（Endotoxin）

Less than 1.0 EU per μg by the LAL method.

純度（Purity）

>95% as determined by SDS-PAGE.

制劑（Formulation）

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重構(gòu)方法（Reconstitution）

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存儲(chǔ)（Storage）

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

-20°C to -70°C for 12 months in lyophilized state;

-70°C for 3 months under sterile conditions after reconstitution.

LILRA2分子背景

LILRA2（白細(xì)胞免疫球蛋白樣受體A2），也稱(chēng)為CD85H和LIR7（白細(xì)胞抗體樣受體7）。它屬于LIR受體（LILRAs）的A亞家族，是具有2-4個(gè)細(xì)胞外Ig樣結(jié)構(gòu)域、一個(gè)跨膜結(jié)構(gòu)域（TM）和一個(gè)短細(xì)胞質(zhì)尾部的單程I型跨膜蛋白。LILRA2在細(xì)胞外區(qū)域含有4個(gè)Ig樣C2型結(jié)構(gòu)域。LILRA2不結(jié)合I類(lèi)MHC抗原。LILRA2主要在單核細(xì)胞和B細(xì)胞上表達(dá)，在樹(shù)突狀細(xì)胞和自然殺傷細(xì)胞上表達(dá)水平較低。LILRA2是一種激活受體，可抑制樹(shù)突細(xì)胞分化和抗原呈遞，并抑制先天免疫反應(yīng)。